Addex Therapeutics (ADXN) versus Its Rivals Financial Analysis

Addex Therapeutics (NASDAQ:ADXN – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Addex Therapeutics to similar companies based on the strength of its analyst recommendations, institutional ownership, dividends, earnings, valuation, profitability and risk.

Volatility and Risk

Addex Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Comparatively, Addex Therapeutics’ competitors have a beta of -0.05, indicating that their average stock price is 105% less volatile than the S&P 500.

Insider & Institutional Ownership

16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 15.0% of Addex Therapeutics shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Addex Therapeutics and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Addex Therapeutics $210,000.00 -$8.12 million -0.64
Addex Therapeutics Competitors $3.55 billion $3.17 billion 559.01

Addex Therapeutics’ competitors have higher revenue and earnings than Addex Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and price targets for Addex Therapeutics and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Addex Therapeutics 1 0 0 0 1.00
Addex Therapeutics Competitors 7845 13798 25820 1039 2.41

As a group, “Pharmaceuticals” companies have a potential upside of 24.59%. Given Addex Therapeutics’ competitors stronger consensus rating and higher probable upside, analysts clearly believe Addex Therapeutics has less favorable growth aspects than its competitors.

Profitability

This table compares Addex Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Addex Therapeutics N/A -174.44% -126.47%
Addex Therapeutics Competitors -2,400.61% -215.91% -15.58%

Summary

Addex Therapeutics competitors beat Addex Therapeutics on 9 of the 13 factors compared.

Addex Therapeutics Company Profile

(Get Free Report)

Addex Therapeutics is a Swiss biotechnology company focused on discovering and developing small-molecule medicines that act on metabotropic glutamate receptors. Its research uses allosteric modulators, which bind to sites on receptors distinct from the sites targeted by naturally occurring neurotransmitters. The company’s programs have included dipraglurant, an investigational mGlu5 negative allosteric modulator studied for Parkinson’s disease-related movement disorders, and ADX71149, an mGlu2 positive allosteric modulator developed in collaboration with Janssen for neurological and psychiatric conditions.

Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.